Clinical Trials
2 trialsNCT01337050 2015-10-28
Asian Phase I Study Of PF-03446962
Pfizer
Phase 1 Completed
NCT01911273 2015-10-28
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
Pfizer
Phase 2 Terminated